The New England Patriots appear to be content with wide receiver Stefon Diggs after his return to OTAs. Patriots offensive ...

Six high school seniors from Montgomery County are in rare company.  They are semifinalists in this year’s U.S. Presidential ...

Kymera Therapeutics, Inc. (NASDAQ:KYMR) just reported positive results from its phase 1 healthy volunteer study using KT-621. The purpose of this clinical candidate is to develop it as an oral ...

Kymera Therapeutics (NASDAQ:KYMR) Monday reported positive Phase 1 results from its healthy volunteer study of KT-621, a first-in-class oral STAT6 degrader, sending shares up +35% in premarket ...

Kymera Therapeutics shares rose after it disclosed positive clinical results from the Phase 1 healthy volunteer study of KT-621. Shares were up 13% to $33.49 in premarket trading on Monday.

“Our primary objective was to demonstrate that KT-621 could achieve robust STAT6 degradation in blood and skin that was well tolerated, and these results go well beyond our expectation ...

Complete STAT6 degradation achieved in both blood and skin at all MAD doses ≥50 mg KT-621 impact on Th2 biomarkers in line or superior to dupilumab with median TARC reduction up to 37% and ...

Complete STAT6 degradation achieved in both blood and skin at all MAD doses ≥50 mg KT-621 impact on Th2 biomarkers in line or superior to dupilumab with median TARC reduction up to 37% and median ...

Investing.com -- Shares of Kymera Therapeutics Inc (NASDAQ: KYMR) surged 37.3% premarket following the announcement of encouraging Phase 1 trial results for KT-621, a novel oral STAT6 degrader.The ...

On June 2, Kymera Therapeutics Inc. (NASDAQ:KYMR) announced positive first-in-human results from its Phase 1 healthy volunteer clinical trial of KT-621, which is a first-in-class, oral STAT6 degrader.